Dogwood Therapeutics, Inc. has 3 Schedule 13D or 13G filings on record since 2025-11-25. 2 holders' latest filing reports 5% or more of common stock, par value $0.0001. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Sealbond Limited | 83% | 21,822,333 | SCHEDULE 13D/A, 2025-11-25 | 2025-11-21 |
| Armistice Capital, LLC | 9.99% | 3,384,798 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Purpose of Transaction (Item 4)
Sealbond Limited
Item 4 of the Schedule 13D is hereby amended and restated as follows: Registration Rights Agreement On October 7, 2024, in connection with the Exchange Agreement, the Company and Sealbond entered into a Registration Rights Agreement (the "Registration Rights Agreement"). Pursuant to the Registration Rights Agreement, if, at any time after April 30, 2025, the Company receives a request from holders of at least forty percent (40%) of the Registrable Securities (as defined in the Registration Rights Agreement) then outstanding that the Company file a Form S-1 registration statement with respect to at least thirty percent (30%) of the Registrable Securities then outstanding; provided, that, if at the time of such request, the only holder of Registrable Securities is Sealbond, there shall be no threshold percent to make such request and such threshold percent that must be covered by such request shall be thirty percent (30%) (or, in each case, a lesser percent if the anticipated aggregate offering price, net of Selling Expenses (as defined in the Registration Rights Agreement), would exceed $10,000,000), then the Company shall as soon as practicable, and in any event within sixty (60) days after the date of such request, file a Form S-1 registration statement with the SEC. If, at any time after April 30, 2025, the Company receives a request from holders of at least thirty percent (30%) of the Registrable Securities then outstanding that the Company file a Form S-3 …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-11-25; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-25 | Sealbond Limited | 83% | SCHEDULE 13D/A |
| 2026-05-15 | Armistice Capital, LLC | 9.99% | SCHEDULE 13G |
| 2026-08-14 | Armistice Capital, LLC | 9.99% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Dogwood Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.